Involvement of liver kinase B1 in the ameliorative action of epigallocatechin-3-gallate against MAFLD progression in mice
Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by intrahepatic fat accumulation in individuals without a history of excessive alcohol consumption. This study investigated the effects of epigallocatechin-3-gallate (EGCG) on reducing MAFLD severity. Twenty-four ddY mice...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pensoft Publishers
2025-08-01
|
| Series: | Pharmacia |
| Online Access: | https://pharmacia.pensoft.net/article/159024/download/pdf/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238917270732800 |
|---|---|
| author | Mahardian Rahmadi Chia-Wei Phan Santhra Segaran Balan Athallah Syauqi Zumarthana Ellyna Majesty Ayundari Ismailia Wienda Yasmin Pratama Putri Salsabila Ahmad Dzulfikri Nurhan |
| author_facet | Mahardian Rahmadi Chia-Wei Phan Santhra Segaran Balan Athallah Syauqi Zumarthana Ellyna Majesty Ayundari Ismailia Wienda Yasmin Pratama Putri Salsabila Ahmad Dzulfikri Nurhan |
| author_sort | Mahardian Rahmadi |
| collection | DOAJ |
| description | Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by intrahepatic fat accumulation in individuals without a history of excessive alcohol consumption. This study investigated the effects of epigallocatechin-3-gallate (EGCG) on reducing MAFLD severity. Twenty-four ddY mice were divided into three groups: normal feed, high-fat diet (HFD), and HFD + 25 mg/kg EGCG supplementation. All mice were provided with food and water ad libitum; the remaining feed and body weight were measured daily for 28 days. On the 15th day, the therapy group received EGCG intraperitoneally. At the end of the study, mice were sacrificed, and their livers were collected for histopathological examination and measurement of LKB1, CD86, and CD163 mRNA expression. The results indicated that LKB1 expression increased significantly following EGCG administration. Additionally, histopathological analysis revealed a positive impact of EGCG on hepatocyte repair. In conclusion, the 14-day EGCG treatment demonstrated promising results in improving liver health in mice with MAFLD and modulating LKB1 expression. |
| format | Article |
| id | doaj-art-bf2d037a016d48ee835d805ce3ea5b0e |
| institution | Kabale University |
| issn | 2603-557X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Pensoft Publishers |
| record_format | Article |
| series | Pharmacia |
| spelling | doaj-art-bf2d037a016d48ee835d805ce3ea5b0e2025-08-20T04:01:18ZengPensoft PublishersPharmacia2603-557X2025-08-017211110.3897/pharmacia.72.e159024159024Involvement of liver kinase B1 in the ameliorative action of epigallocatechin-3-gallate against MAFLD progression in miceMahardian Rahmadi0Chia-Wei Phan1Santhra Segaran Balan2Athallah Syauqi Zumarthana3Ellyna Majesty Ayundari4Ismailia Wienda Yasmin Pratama Putri5Salsabila6Ahmad Dzulfikri Nurhan7Universitas AirlanggaUniversity of MalayaManagement and Science UniversityUniversitas AirlanggaUniversitas AirlanggaUniversitas AirlanggaUniversitas AirlanggaTaipei Medical UniversityMetabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by intrahepatic fat accumulation in individuals without a history of excessive alcohol consumption. This study investigated the effects of epigallocatechin-3-gallate (EGCG) on reducing MAFLD severity. Twenty-four ddY mice were divided into three groups: normal feed, high-fat diet (HFD), and HFD + 25 mg/kg EGCG supplementation. All mice were provided with food and water ad libitum; the remaining feed and body weight were measured daily for 28 days. On the 15th day, the therapy group received EGCG intraperitoneally. At the end of the study, mice were sacrificed, and their livers were collected for histopathological examination and measurement of LKB1, CD86, and CD163 mRNA expression. The results indicated that LKB1 expression increased significantly following EGCG administration. Additionally, histopathological analysis revealed a positive impact of EGCG on hepatocyte repair. In conclusion, the 14-day EGCG treatment demonstrated promising results in improving liver health in mice with MAFLD and modulating LKB1 expression.https://pharmacia.pensoft.net/article/159024/download/pdf/ |
| spellingShingle | Mahardian Rahmadi Chia-Wei Phan Santhra Segaran Balan Athallah Syauqi Zumarthana Ellyna Majesty Ayundari Ismailia Wienda Yasmin Pratama Putri Salsabila Ahmad Dzulfikri Nurhan Involvement of liver kinase B1 in the ameliorative action of epigallocatechin-3-gallate against MAFLD progression in mice Pharmacia |
| title | Involvement of liver kinase B1 in the ameliorative action of epigallocatechin-3-gallate against MAFLD progression in mice |
| title_full | Involvement of liver kinase B1 in the ameliorative action of epigallocatechin-3-gallate against MAFLD progression in mice |
| title_fullStr | Involvement of liver kinase B1 in the ameliorative action of epigallocatechin-3-gallate against MAFLD progression in mice |
| title_full_unstemmed | Involvement of liver kinase B1 in the ameliorative action of epigallocatechin-3-gallate against MAFLD progression in mice |
| title_short | Involvement of liver kinase B1 in the ameliorative action of epigallocatechin-3-gallate against MAFLD progression in mice |
| title_sort | involvement of liver kinase b1 in the ameliorative action of epigallocatechin 3 gallate against mafld progression in mice |
| url | https://pharmacia.pensoft.net/article/159024/download/pdf/ |
| work_keys_str_mv | AT mahardianrahmadi involvementofliverkinaseb1intheameliorativeactionofepigallocatechin3gallateagainstmafldprogressioninmice AT chiaweiphan involvementofliverkinaseb1intheameliorativeactionofepigallocatechin3gallateagainstmafldprogressioninmice AT santhrasegaranbalan involvementofliverkinaseb1intheameliorativeactionofepigallocatechin3gallateagainstmafldprogressioninmice AT athallahsyauqizumarthana involvementofliverkinaseb1intheameliorativeactionofepigallocatechin3gallateagainstmafldprogressioninmice AT ellynamajestyayundari involvementofliverkinaseb1intheameliorativeactionofepigallocatechin3gallateagainstmafldprogressioninmice AT ismailiawiendayasminpratamaputri involvementofliverkinaseb1intheameliorativeactionofepigallocatechin3gallateagainstmafldprogressioninmice AT salsabila involvementofliverkinaseb1intheameliorativeactionofepigallocatechin3gallateagainstmafldprogressioninmice AT ahmaddzulfikrinurhan involvementofliverkinaseb1intheameliorativeactionofepigallocatechin3gallateagainstmafldprogressioninmice |